About MolMed
MolMed is a company based in Milano (Italy) founded in 1996 was acquired by AGC Biologics in July 2020. MolMed offers products and services including CAR-T Platform, CAR-NK, Viral Vectors, and Genetically Modified Cells. MolMed operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, Celgene and ATAI, among others.
- Headquarter Milano, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Molmed S.P.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2.1 M (USD), Grant
Jan 01, 2017
-
Investors
European Union
& 1 more
-
Employee Count
Not available
-
Acquired by
AGC Biologics
(Jul 27, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MolMed
MolMed offers a comprehensive portfolio of products and services, including CAR-T Platform, CAR-NK, Viral Vectors, and Genetically Modified Cells.
Develops therapies using genetically modified T cells for cancer.
Provides treatments with modified natural killer cells for oncology.
Enables gene delivery for research and clinical applications.
Supports production of customized cells for therapy development.
People of MolMed
Unlock access to complete
Unlock access to complete
Funding Insights of MolMed
Investors in MolMed
MolMed has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and AGC Biologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Provides contract development and manufacturing for biopharmaceuticals worldwide.
|
Locked | Locked | Locked |
Investor details for MolMed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MolMed
Investment portfolio details for MolMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MolMed
Detailed financials for MolMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Molmed Comparisons
Peer comparison for MolMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MolMed
MolMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, Celgene and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
Detailed competitors of MolMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Molmed
Complete news archive for MolMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MolMed
MolMed was founded in 1996 and raised its 1st funding round 21 years after it was founded.
MolMed is headquartered in Milano, Italy.
MolMed was founded in 1996 in Milano, Italy, within the biotechnology sector. Gene and cell therapies are developed by the company to address cancer and rare diseases. The pipeline features Zalmoxis (TK), a cell-based treatment for acute leukemia; NGR-hTNF, targeted at solid tumors; and CAR-CD44v6, an immuno-gene therapy for hematological malignancies and various epithelial tumors. Operations center on advancing these therapeutic innovations.
MolMed's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
MolMed offers CAR-T Platform, CAR-NK, Viral Vectors, and Genetically Modified Cells.
MolMed has 2 investors. Key investors include European Union, and AGC Biologics.